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A major challenge in neurological gene therapy is safe delivery of transgenes to sufﬁcient
cell numbers from the circulation or periphery. This is particularly difﬁcult for diseases
involving spinal cord motor neurons such as amyotrophic lateral sclerosis (ALS). We
have examined the feasibility of non-viral gene delivery to spinal motor neurons from
intraperitoneal injections of plasmids carried by “immunogene” nanoparticles targeted
for axonal retrograde transport using antibodies. PEGylated polyethylenimine (PEI-PEG12)
as DNA carrier was conjugated to an antibody (MLR2) to the neurotrophin receptor p75
(p75NTR). We used a plasmid (pVIVO2) designed for in vivo gene delivery that produces
minimal immune responses, has improved nuclear entry into post mitotic cells and
also expresses green ﬂuorescent protein (GFP). MLR2-PEI-PEG12 carried pVIVO2 and
was speciﬁc for mouse motor neurons in mixed cultures containing astrocytes. While
only 8% of motor neurons expressed GFP 72 h post transfection in vitro, when the
immunogene was given intraperitonealy to neonatal C57BL/6J mice, GFP speciﬁc motor
neuron expression was observed in 25.4% of lumbar, 18.3% of thoracic and 17.0% of
cervical motor neurons, 72 h post transfection. PEI-PEG12 carrying pVIVO2 by itself did
not transfect motor neurons in vivo, demonstrating the need for speciﬁcity via the p75NTR
antibody MLR2. This is the ﬁrst time that speciﬁc transfection of spinal motor neurons
has been achieved from peripheral delivery of plasmid DNA as part of a non-viral gene
delivery agent. These results stress the speciﬁcity and feasibility of immunogene delivery
targeted for p75NTR expressing motor neurons, but suggests that further improvements
are required to increase the transfection efﬁciency of motor neurons in vivo.
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INTRODUCTION
Targeted gene therapy has the potential to be developed for dis-
eases involvingdeathof motorneurons such as amyotrophic lateral
sclerosis (ALS). Motor neurons can be transfected by injecting
every muscle innervated by spinal motor neurons. Transport of
therapy is then by axonal pathways originating from, terminating
in, or passing through the injection site. However, this requires
many painful injections and even then, it may not be possible to
reach all spinal motor neurons (Towne et al., 2011). Alternatively
motor neurons can be difﬁcult to access and transfect from the
circulation or centrally through injections into the cerebrospinal
ﬂuid (CSF). Peripheral injections of viral gene therapy have not
been successful at selectively targeting motor neurons (Towne
et al., 2008). The blood brain barrier (BBB) is also effective at
keeping toxins and infectious material out of the central nervous
system (CNS; Pardridge, 2006). Our group has been developing
targeted gene delivery agents called “immunogenes” with the aim
of using them to deliver therapeutic genes to diseased motor neu-
rons (Rogers and Rush, 2012). They are composed of antibodies
that internalize after targeting cell surface receptors and are conju-
gated to cationic carriers, able to condenseDNA/RNA, forming the
immunogene. Cells that express the cognate cell-surface receptors
of the targeting antibody can therefore be speciﬁcally transfected
with immunogenes in vivo from the circulation (Rogers and Rush,
2012).
Antibodies that internalize into target cells are essential for
immunogenes. We previously used an antibody (clone MC192)
to the rat common neurotrophin receptor p75 (p75NTR) as a
targeting agent (Barati et al., 2006). p75NTR is a receptor highly
expressed on motor neurons during the embryonic period, down
regulated in adulthood (Yan and Johnson, 1988), only to be
re-expressed following neuronal injury, including ALS (Lowry
et al., 2001). Past research has revealed that p75NTR is retro-
gradely trafﬁcked in signaling endosomes in motor neurons when
taken up by at distal terminals (Lalli and Schiavo, 2002), ren-
dering this receptor ideally suited to deliver therapeutic genes
for motor neurons. Transport from the periphery to motor neu-
rons should be possible using antibodies that target rat p75NTR
(Bronfman et al., 2003), i.e., MC192 and pan speciﬁc MLR2
(Rogers et al., 2006; Matusica et al., 2008). Both have been demon-
strated to internalizewith the receptormaking them ideal targeting
agents.
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The development of immunogenes as targeted nanocarriers
is particularly attractive for diseases such as ALS. In almost all
cases of ALS, death occurs within 3–5 years of diagnosis due to
the selective death of motor neurons and there are no effective
therapies (Turner et al., 2013). We have previously used immuno-
genes to deliver therapeutic glial-derived growth factor (GDNF)
to injured motor neurons in vivo in neonatal rats (Barati et al.,
2006). The rat speciﬁc p75NTR antibody MC192 was conju-
gated to a cationic polymer poly(L-lysine; PLL) to condense
plasmids expressing GDNF and the immunogene was given intra-
muscularly (Barati et al., 2006). Although GDNF rescued motor
neurons that innervated injected muscles, this ﬁrst generation
immunogene could not be used in the circulation to access larger
pools of motor neurons (Barati et al., 2006), making it vulnera-
ble to rapid degradation. Cytotoxicity in vivo can be associated
with the surface charge of the polymer (Chollet et al., 2002)
and poor stability is associated with interactions with erythro-
cytes and serum components such as albumin, lipoproteins or
IgG (Rogers and Rush, 2012). These issues can be overcome
by masking the surface charge with agents such as polyethy-
lene glycol (PEG). Forming a hydrophilic shell, PEG limits the
hydrophobic or electrostatic interactions with the extracellular
medium and prevents binding of the cationic polymer with ery-
throcytes and plasma proteins (Chollet et al., 2002; Rogers and
Rush, 2012). Hence, such measures are required for stealth in the
circulation.
After entering cells, non-viral gene delivery agents must be able
to escape the endosome/lysosomal compartments to deliver their
payloadof DNAorRNAto thenucleus andRNA-induced silencing
complex (RISC) complex, respectively, (Rogers and Rush, 2012).
Our ﬁrst generation immunogene used PLL that required fuso-
genic peptides to escape endosomal/lysososomal compartments of
cells (Navarro-Quiroga et al., 2002). Other DNA/RNA condensing
agents such as polyethylenimine (PEI) have more useful proper-
ties including a mechanism for endosomal escape. PEI possesses
a high cationic charge density due to secondary amino groups
that enables the endosomal/lysosomal release of complexes due
to the so-called “proton sponge effect” (Boussif et al., 1995; Tang
and Szoka, 1997; Lungwitz et al., 2005). PEI unlike PLL also facil-
itates the entry of plasmid DNA into the nucleus (Godbey et al.,
1999).
Toxicity of intravenously administered cationic polyplexes can-
not only be reduced by PEGylation (Merdan et al., 2003; Ogris
et al., 2003; Malek et al., 2009) but also when nanoconstructs are
also endowed with antibodies or other targeting moieties (Zhang
et al., 2003; Luo et al., 2010; Höbel et al., 2011; Schaffert et al.,
2011). This may be reﬂective of speciﬁcity in addition to lower
toxicity because of reduction in charge after conjugation to for
example an antibody. Besides systemic toxicities, cytotoxic effects
are also observed upon polyplex internalization. Since polycations
electrostatically bind and condense DNA, non-speciﬁc electro-
static binding to any kind of cellular polyanions (e.g., enzymes,
mRNA, or genomic DNA) may deregulate the expression proﬁle
of housekeeping genes (Godbey et al., 2001) or induce activation
of genes involved in apoptosis (Masago et al., 2007). Consequently,
characteristics of cationic polyplex formulations such asmolecular
weight, cationic charge density and the presence of free polymer
also inﬂuence their cytotoxicity (Kunath et al., 2003; Boeckle et al.,
2004; van Gaal et al., 2011). Accordingly, we hypothesize that an
ideal candidate for a safe non-viral gene delivery vector is a car-
rier with a neutral to slightly negative charge and the capability of
being targeted to the cell type required.
In addition to targeting cells from the periphery, we also aimed
to improve the expression of transgenes. Methods to improve
nuclear import of plasmids are of particular importance in post
mitotic cells such as motor neurons. Transfection rates can be
poor in post mitotic cells as there is limited breakdown of the
nuclear envelope (Zabner et al., 1995). Therefore, modifying plas-
mids to improve nuclear entry is required. One way of achieving
this is to include in the plasmid design a DNA targeting sequence
(DTS) that bind to endogenously expressed transcription fac-
tors that then act as nuclear localization sequences (NLSs) and
improve nuclear import (Mandke and Singh, 2012). Plasmid vec-
tors also often contain sites that can produce innate immune
responses through unmethylated cytosine guanine bases separated
by only one phosphate (CpGs; Magnusson et al., 2011). Removal
of CpGs from the plasmid backbone has been shown to reduce
immune reactions to plasmids and prolong expression in vivo
(Magnusson et al., 2011; Davies et al., 2012). Hence, plasmids that
are chosen for in vivo delivery should include DTS and minimal
CpGs.
Here, we report on the development and evaluation of
immunogenes capable of targeting motor neurons in vitro and
in vivo. We demonstrate speciﬁcity of delivery to motor neurons
can be achieved from peripheral injections using p75NTR anti-
body MLR2. We show that nanocarriers comprised of p75NTR
antibody MLR2 conjugated to PEGylated PEI can deliver plasmids
to mouse motor neurons in vitro and in vivo. In addition, we
demonstrate gene expression in motor neurons in vivo using plas-
mids designed for improved nuclear entry and less immunogenic-
ity. Hence, we explore the potential of using p75NTR-targeting
immunogenes as gene therapy.
MATERIALS AND METHODS
PREPARATION OF NANOCONSTRUCTS
Branched PEI (C24H59N11PEI, molecular weight 25 kDa; Sigma
Aldrich, Australia) was made to 20 mg/ml in H2O and depro-
tonated with HCl to pH 7.0. PEI was then buffer exchanged on
PD10 columns (GE, Australia) with 20 mM 4-(2-hydroxyethyl)-
1-piperazine ethane sulfonic acid (HEPES; Invitrogen, Aust),
250 mM NaCl, and pH 7.9. 50 mg of PEI was PEGylated
with a branched PEG reagent (Methyl-PEO12)3-PEO4-NHS ester
(Thermo Scientiﬁc, Rockford, IL, USA) with a molecular weight
of 2421 g/mol, (Figure 1). This was achieved at a molar ratio
of 10:1 PEG to PEI. The number of PEGs per PEI was analyzed
by spectral analysis using a Varian 300 MHz NMR spectrometer
NMR with deuterium oxide (D2O) as the solvent indicating on
average 12 PEG moieties conjugated per PEI, corresponding to
6% of amines on the PEI being PEGylated. Hybridoma MLR2 was
grown and MLR2 puriﬁed on protein G column as previously
described (Rogers et al., 2006). Conjugation of PEI-PEG12 or
PEI to anti-p75NTR MLR2 was achieved using methods adapted
from Blessing et al. (2001) and Germershaus et al. (2006). Brieﬂy,
the cross-linker N-succinimidyl 3-(2-pyridyldithio)propionate
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FIGURE 1 | Stepwise synthesis of PEGylated PEI.
(SPDP; Sigma Aldrich, Australia) was used to produce SPDP-
activated PEI-PEG12, PEI, and MLR2 IgG. A molar ratio of 1.62
SPDP to PEI was found to generate one functional SPDP-activated
PEI-PEG12. PEI without PEG12 was also functionalized using the
same method but at a molar ratio of 1.3 SPDP to PEI to gener-
ate one SPDP activated PEI. Twenty molar excess DTT was used
to generate a thiol-functionalized PEI-PEG12 and PEI. The reac-
tions were all conducted for 1 h. MLR2 IgG was activated with
SPDP (at a molar ratio of 4 SPDP: 1 IgG for 2 h), to produce 1
functional SPDP-activatedMLR2. Toproduce the conjugate, thiol-
functionalized PEI-PEG12 or PEI was mixed with SPDP-activated
MLR2 at a molar ratio of 2:1, and reacted for 24 h under nitrogen
gas atmosphere. The amount of PEI-PEG12 or PEI per IgG was
calculated as 1.3 to 1 after measuring the release of pyridine-2-
thione (343 nm). All reactions were in a reaction buffer of 20 mM
HEPES, 250 mM NaCl, pH 7.9, and after each step constructs
were puriﬁed by gel ﬁltration on PD-10 columns. PEI concentra-
tion was calculated by TNBS (2,4,6-trinitrobenzene sulfonic acid)
assay using a standard PEI dilution curve as previously described
(Snyder and Sobocinski, 1975). The conjugate was puriﬁed using
cation exchange onHiTrap SP Sepharose (GE,Australia)with step-
wise NaCl elution of 1.0, 2.0, and 3.0 M NaCl in 20 mM HEPES
pH 7.2. The MLR2-PEI-PEG12 conjugate was eluted with 2.0 M
NaCl, and the construct MLR2-PEI with 3.0 M NaCl. A 100 kDa
cut-off Ultra 4 (Millipore) centrifuge column was used to replace
the high salt with isotonic buffer (20 mM HEPES, 0.15 M NaCl,
pH 7.3.
PREPARATION OF PLASMID DNA
An enhanced green ﬂuorescent protein (GFP) expressing plasmid
was from Aldevron (pgWiZ; Fargo, ND, USA). This plasmid was
used for some in vitro transfection experiments and although pro-
duces sustained GFP expression it can induce immune responses
in vivo (Chamarthy et al., 2003; Grønevik et al., 2005; Rose et al.,
2014). Hence for in vivo work a bicistronic pVIVO2 plasmid
(9.6 kb) was purchased from Invivogen (San Diego CA, USA).
pVIVO2 includes a SV40DNAtargeting signal (DTS) for improved
nuclear entry with cytosine and guanine separated by only one
phosphate (CpG) motifs removed from the plasmid backbone to
reduce immune reactions in vivo (Davies et al., 2012). pVIVO2
also contains two human ferritin composite promoters, FerH
(heavy chain) and FerL (light chain) combined with SV40 and
CMV enhancers for GFP and LacZ expression, respectively. Com-
petent Escherichia coli cells were transformed with pgWiZ or
pVIVO2 plasmids and puriﬁed using Endotoxin Free Maxi Prep
Kits (Qiagen) as per the manufacturer’s instructions.
SIZE AND ZETA POTENTIAL AND GEL RETARDATION
Nanoconstructs were subject to size (nm) and charge measure-
ments (zeta potential in mV) using a Malvern Zetasizer Nano.
Zeta potential is a measure of the magnitude of particle charge
in solution. Brieﬂy, MLR2-PEI-PEG12 or PEI-PEG12 was mixed
with plasmid (pgWiZ) at a nitrogen (amine) to phosphate (DNA)
ratio (N/P) of 2, 5, 10, and 12 in sample buffer (20 mM HEPES,
0.15 M NaCl, pH 7.3). Samples were placed in a disposable cap-
illary cell (DTS 1060) where both zeta potential and particle size
were measured. The charge at each N/P ratio was analyzed in
gel-retardation assays as described (Kircheis et al., 1997). Brieﬂy,
samples (10 μl) containing 400 ng pDNA and varying amount
of conjugate at different N/P ratios were applied to 1% agarose
gels made in Tris-Borate-EDTA buffer with GelRedTM at 1/10,000
(Biotium, Hayward, CA, US) at 100 V for 60 min. The gel was
then imaged on a using BioRad Gel Doc 2000 transilluminator
(Bio-Rad Laboratories, Hercules, CA, USA).
CELL CULTURE AND CYTOTOXICITY ASSAYS
Primary motor neurons (PMN) were isolated from E12.5 embry-
onic mouse (C57BL/6J) spinal cords as previously described
(Wiese et al., 2010) or as mixed motor neuron/glia cultures (Ford
et al., 1994) and cells cultured on 48-well plates (Nunc) coatedwith
poly-D-ornithine/laminin (Wiese et al., 2010). Motor neurons
were grown in Neurobasal media (Invitrogen) supplemented with
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10% horse serum, GlutaMAX, B27 supplement (Invitrogen) and
10 nM β-mercaptoethanol and BDNF and CNTF (10 ng/ml; Invit-
rogen, Aust) as previously described (Wiese et al., 2010). Plasmids
used for transfection were pgWiZ or pVIVO2 (both express-
ing GFP). Motor neurons were transfected in cell culture media
(without horse serum or β-mercaptoethanol) for 4 h using the
polyplexes MLR2-PEI, MLR2-PEI-PEG12, PEI-PEG12, and 20 μg
of plasmid (pGwiZ or pVIVO2). Transfectants were removed after
4 h before replacing with full culture media. Viable motor neu-
rons were examined before and after transfection for a total of
7 days in ﬁve separate wells using a Leica IX70 inverted ﬂuores-
cence microscope. Transfection was measured by counting motor
neurons expressing GFP detected by microscopy as a percentage of
motor neurons plated in at least ﬁve wells. Mouse NSC34 motor
neuron-like cells, human SHSY5Y and ﬁbroblast control cells were
cultured as previously described (Rogers et al., 2010; Shepheard
et al., 2014). Flow cytometry for determining labeled antibody
speciﬁcity is exactly as described previously (Rogers et al., 2010)
using an Accuri C6 Flow Cytometry (BD).
ANTIBODY AND GENE DELIVERY IN C57BL/6J MICE
Approval to undertake experiments using C57BL/6J mice
described in this current study was by the Flinders University
Animal Welfare Committee. Antibody to p75NTR (MLR2) was
labeled with 4 ﬂuorescent dye molecules (Atto-488-NHS-Ester;
Sigma) per antibody molecule, as described by the manufacturer.
The degree of labeling (DOL) was determined by absorbance
of labeled antibody at 501 and 280 nm with the appropriate
extinction coefﬁcients and corrections for DOL. Intraperitoneal
injections of labeled antibody or immunogenes were given to new-
born C57BL/6J neonatal mice, always in two equal doses. After
3–4 days, mice were euthanized and transcardially perfused with
PBS containing 1% sodium nitrite, followed by Zamboni’s ﬁxative
(4% paraformaldehyde (w/v), 7.5% saturated picric acid (v/v),
PBS, pH 7.4). Spinal cords and dorsal root ganglia (DRG) were
removed and post ﬁxed overnight in Zamboni’s ﬁxative at 4◦C and
then cryoprotected in PBS containing 30% sucrose (w/v). 30 and
10 μm sections were cut from spinal cords and DRGs embedded in
OCT on a cryostat. Sections were blocked in blocking diluent (PBS
with 10% donkey serum (Sigma-Aldrich), 0.2% Tween-20, 0.02%
azide) and antibodies incubated in antibody diluent (PBS with
1%donkey serum (Sigma-Aldrich), 0.2%Tween-20, 0.02%azide).
Primary antibodies used were rabbit anti homeobox transcription
factor 9 (Hb9 used at 1:1000; Abcam, unavailable post 2012); rab-
bit anti-Choline Acetyltransferase (ChAT) P3YEB (a generous gift
from Prof Dr. M. Schemann, Techn Univ Munich, 1:5000), and
goat anti-mouse p75NTR (Sigma; 1 μg/ml) and chicken anti-GFP
(Biosensis; 1/500). Secondary antibodies included donkey anti
sheep-488, donkey anti rabbit-CY3, and donkey anti-chicken-488
(Jackson ImmunoResearch Laboratories). All secondary antibod-
ies were diluted to 1:800. Imaging was carried out on an Olympus
BX50 ﬂuorescence microscope.
RESULTS
CONSTRUCTION AND CHEMICAL PROPERTIES OF NANOCONSTRUCTS
Branched PEI was used as a DNA condensing agent in the
nanoconstructs. Each PEI molecule was PEGylated with 12 PEG
moieties, each being 2.4 kDA in molecular weight (Figure 1). To
engineer speciﬁcity of nanoconstructs for motor neurons express-
ing the cell surface receptor p75 neurotrophin receptor (p75NTR),
PEI-PEG12 was conjugated to a monoclonal antibody p75NTR
(MLR2; Rogers et al., 2006) using methods adapted from Blessing
et al. (2001) and Germershaus et al. (2006) and shown in Figure 2.
The ﬁnal construct contains a disulﬁde bond between an amine
on the antibody and an amine on the PEI.
Gel retardation was used to monitor electrostatic interactions
between cationic amines (Nitrogen) in the PEI and the anionic
phosphate group of the plasmid DNA (pgWiZ or pVIVO2). This
procedure showed the PEI (N): plasmid (P) DNA ratio required
to generate a neutral complex. Figure 3 shows that an N/P of 10
(lane 7) and 12 (lane 8) retarded the complex MLR2-PEI-PEG12-
pVIVO2 in the loading well. This is in contrast to PEI-PEG12-
pVIVO2 where the complex was retarded with a N/P of 5 (lane 3),
indicating that the full immunogene had a less positive charge than
PEGylated PEI lacking the antibody. Exactly the same results were
obtained if pVIVO2 was replaced with pgWiZ. The charge of the
immunogene was conﬁrmed by measuring zeta potential. Table 1
shows that MLR2-PEI-PEG12 complexed to pgWiZ at N/P 12 had
a zeta potential of −19.91 ± 1 mV, in contrast to PEI-PEG12
complexed to pgWiZ with a zeta potential of 4.8 ± 0.9 mV at N/P
12. The size of the MLR2-PEI-PEG12 complexed to plasmid at
N/P 12 was 95.3 ± 11 nm, indicating that the DNA was condensed.
PEI-PEG12 was 101.1 ± 16.1 nm in size at N/P 12.
CYTOTOXICITY AND IN VITRO SPECIFICITY OF NANOCONSTRUCTS
We next examined the cytotoxicity and transfection ability of
immunogenes formotor neurons in vitro. PMNwere isolated from
embryonic mice as previously described (Wiese et al., 2010) in 48-
well plates and 4 days later transfected with plasmids (pgWiZ or
pVIVO2) expressing GFP, using MLR2-PEI or MLR2-PEI-PEG12.
We counted viable motor neurons before and after transfection
(Figure 4A) for a total of 7 days (n = 3 motor neuron isola-
tions in ﬁve separate wells). The viability of cells transfected with
MLR2-PEI-PEG12-pgWiz was not signiﬁcantly different than for
non-transfected cells over this time period. 48 h and 72 h post
transfection with MLR2-PEI-PEG12-pGwiZ there were 46.4 ± 3.5
and 41.1 ± 0.7% of the original viable motor neurons present.
This was not signiﬁcantly different from control non-transfected
cells where there were 57.7 ± 2.4 and 51.2 ± 2.7% of original
viable motor neurons present at that same time period. However,
when PEI was not PEGylated, the number of live motor neu-
rons was signiﬁcantly (p < 0.001) reduced to 14.2 ± 2.6% then
1.1± 0.35%, 48 and 72 hpost transfectionwithMLR2-PEI-pGwiZ
(Figure 4A). There was no signiﬁcant difference in the percent-
age of live motor neurons if pVIVO2 was used in place of pgWiZ
(results not shown).
GFP expression in pure motor neurons 48 h after transfection is
demonstratedwith pVIVO2 (Figure 4B) or pgWiZ (Figures 4C,D)
carried by MLR2-PEI-PEG12. Figure 4C shows GFP expression in
the cell body and processes of a motor neuron and Figure 4D
shows GFP-containing transfected neuronal processes over a bed
of non-transfected cells. GFP expression was also observed in
motor neurons after transfection with pVIVO2 carried by PEI-
PEG12 (Figures 4E,G), and again there is cell bodies and processes
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FIGURE 2 | Stepwise synthesis of the targeted nanoconstructs.
FIGURE 3 | Agarose gel retardation assay of MLR2-PEI-PEG12-pVIVO2
and PEI-PEG12-pVIVO2. Lane 1, 100 bp ladder; lane 2, naked pVIVO2
(400 ng); lane 3–5 400 ng pVIVO2 with PEI-PEG12 at N/P 5, 10, and 12;
lanes 6–8 400 ng pVIVO2 with MLR2-PEI-PEG12 at N/P 5, 10, and 12.
with GFP and also non-transfected cells. The percentage of motor
neurons expressingGFPwas determined 48 and 72 h post transfec-
tion with MLR2-PEI-PEG12-pgWiz and PEI-PEG12-pgWiz and
MLR2-PEI-pgWiz (Figure 4H). Notably, MLR2-PEI-pgWiz did
not produce any GFP possibly because few live motor neurons
were present after 48 h. However, 8.0 ± 0.8% of motor neurons
expressed GFP 48 h after transfection by MLR2-PEI-PEG12-
pgWiz and this did not increase signiﬁcantly by 72 h (8.3 ± 1.8%).
Similarly, 7.0 ± 1.15% of motor neurons expressed GFP 48 h post
transfection with PEI-PEG12-pgWiz and this rose to 8.1 ± 1.5%
by 72 h post transfection (Figure 4H).
Mixed cultures of motor neurons and astrocytes were iso-
lated from embryonic mice spinal cords (Ford et al., 1994) and
transfected with MLR2-PEI-PEG12-pgWiz or PEI-PEG12-pgWiz.
The percentage of motor neurons transfected after 48 h was
Table 1 | Size and zeta potential of nanoconstructs.
Complex N/P Ratio Zeta potential (mV) Particle size (nm)
PEI-PEG12 2 −14.4 ± 4.7 88.7 ± 13.2
PEI-PEG12 5 −0.5 ± 2.9 78.0 ± 15
PEI-PEG12 10 0.7 ± 3.1 75.8 ± 14
PEI-PEG12 12 4.8 ± 0.9 101.1 ± 16.1
MLR2-PEI-PEG12 5 −42.0 ± 0.4 78.3 ± 14
MLR2-PEI-PEG12 10 −32.5 ± 1.3 82.7 ± 10
MLR2-PEI-PEG12 12 −19.9 ± 1.3 95.3 ± 11
6.7 ± 0.32% for MLR2-PEI-PEG12-pGWIZ and 8.0 ± 1.6% for
PEI-PEG12-pgWiz. However, 8.0 ± 1.6% of astrocytes were trans-
fected with PEI-PEG12-pgWiz and signiﬁcantly (p < 0.001) less
(0.3 ± 0.3%) with MLR2-PEI-PEG12-pgWiz (Figure 4I). This
demonstrates the selectivity of MLR2-PEI-PEG12 for motor neu-
rons. Figure 4F shows GFP expression in astrocytes 48 h post
transfection with PEI-PEG12-pgWiz.
SPECIFICITY OF ANTI-p75NTR (MLR2) AND RETROGRADE TRANSPORT
IN VIVO
Akey requirement for in vivo gene therapy is speciﬁcity to the target
cell population. We used an antibody to p75NTR to target motor
neurons and sought to demonstrate speciﬁcity and usefulness in
neonatal mice where high numbers of motor neurons that express
p75NTR occur. MLR2 was ﬂuorescently labeled with Atto-488)
and the speciﬁcity of the labeled antibody for p75NTR determined
by ﬂow cytometry. Cells expressing mouse p75NTR (Figure 5A)
andhumanp75NTR (Figure 5C)were incubatedwith andwithout
20 μg/ml labeled MLR2 and subjected to ﬂow cytometry analy-
sis. The shift in mean ﬂuorescence intensity to the right indicates
an increase in the antibody binding to the cells. However, there
was no change in ﬂuorescence intensity after control ﬁbroblasts
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FIGURE 4 |Transfection of mouse primary motor neurons (PMN) with
plasmid DNA using targeted nanoconstructs. (A) PMN were isolated
from E12.5 embryos and transfected 3 days later with pGwiZ carried by
MLR2-PEI (open squares) or MLR2-PEI-PEG12 (closed squares). The
number of alive and dead motor neurons for each treatment or no
treatment (closed circles) were counted every 24 h and the % of
neurons that were alive calculated from the original 3000 neurons plated
per well in 48-well plates (n = 5). There was signiﬁcantly (∗∗∗p < 0.001)
less PMN alive after treatment with MLR2-PEI-pGwiZ. (B) Green
ﬂuorescent protein (GFP) expression in live pure motor neurons 48 h after
transfection with by MLR2-PEI-PEG12-pVIVO2. (C,D) GFP expression after
transfection with MLR2-PEI-PEG12-pGwiZ. (E,G) GFP expression in motor
neurons or (F) Astrocytes after transfection with PEI-PEG12-pVIVO2. (scale
bar: 20 μm). (H) The % of original (3000) motor neurons expressing GFP
was determined 48 and 72 h post transfection of pure motor neurons
with MLR2-PEI-PEG12-pGwiZ and PEI-PEG12-pGwiZ. (I). Mixed cultures of
motor neurons and astrocytes were isolated from embryonic mice spinal
cords and 3000 cells plated per well in 48-well plates. The % of
transfected motor neurons and astrocytes were determined 72 h after
transfection with MLR2-PEI-PEG12-pGwiZ and PEI-PEG12-pGwiZ. There
was signiﬁcantly (∗∗∗p < 0.001) less astrocyte transfection with
MLR2-PEI-PEG12-pGwiZ, compared to PEI-PEG12-pGwiZ.
lacking p75NTR were incubated with 20 μg/ml labeled antibody
(Figure 5B), indicating that the antibody indeed speciﬁcally targets
p75NTR-expressing cells. Unlabeled MLR2 (with secondary anti-
mouse antibody labeled with Alexia-Fluor-488) bound to human
SHSY5Y cells as expected (Figure 5D). Unlabeled MLR2 was not
testedonmouseNSC34 cells because the secondary antibodybinds
non-speciﬁcally to mouse derived cells.
Having demonstrated the speciﬁcity of the MLR2 antibody for
p75NTR, we next tested the ability of MLR2 to be retrogradely
transported to spinal cord motor neurons in neonatal mice from
the circulation. Two doses of 75 μg of Atto-488 labeled MLR2
(150 μg total) were injected into neonatal B6 mice (average weight
was 2 g; n = 3) and 36 h later, mice were perfused and spinal
cords excised. Lumbar, thoracic and cervical sections were exam-
ined for motor neuron marker homeobox transcription factor 9
(Hb9; Red; nuclear stain) and labeled MLR2 (green). Representa-
tive micrographs show MLR2 and Hb9 in lumbar (Figure 5E i,ii),
thoracic (Figure 5E iv,v) and cervical (Figure 5E vii,viii) sections.
Merged images (Figure 5E iii,vi,ix) show that the majority of
motor neurons identiﬁed byHb9 also containedMLR2. The extent
of retrograde transport was assessed for lumbar, thoracic and cer-
vical regions by counting the number of motor neurons labeled
with Hb9 and MLR2 and with both labels. Figure 5F shows pooled
results from three mice; 88.6 ± 1.0% lumbar, 95.7 ± 0.5% thoracic
and 87.3 ± 3.8% of cervical motor neurons identiﬁed by Hb9 label
contained MLR2. Hence,MLR2 is efﬁciently transported to motor
neurons from the circulation in neonatal mice. As expected the
motor neurons from mice injected with MLR2-488 also contained
p75NTR (Figure 5G i,ii, and iii) and MLR2-488 was also found in
the p75NTR-expressing neurons of the dorsal root ganglia (DRGs;
Figure 5G iv).
RETROGRADE TRANSPORT AND DELIVERY OF MLR2-PEI-PEG12-PVIVO2
TO MOTOR NEURONS IN VIVO
Given that MLR2 can be retrogradely delivered to the majority
of motor neurons in neonatal mice, we then sought to determine
the extent of gene delivery after injection of our immunogene in
neonatal mice. Initially, neonatal B6 mice (average weight of 2 g)
were injected with two doses of 75 μg MLR2-PEI-PEG12 carrying
58 μg of pgWiZ that expresses GFP and spinal cords examined
72 h later. However, no GFP was observed in spinal motor neu-
rons or elsewhere (data not shown). We then used pVIVO2 that
is designed speciﬁcally to enhance in vivo transfection through
DTS and minimal CpGs. Cells transfected with pVIVO2 were
identiﬁed by GFP expression. Neonatal B6 mice (n = 5; average
weight was 2 g) were injected intraperitonealy twice with 75 μg of
MLR2-PEI-PEG12 carrying 58 μg of pVIVO2, and 72 h later mice
were perfused and spinal cords excised. In addition 75 μg of PEI-
PEG12 carrying 77.3 μg of pVIVO2 was injected twice into three
mice and 72 h later mice were perfused and spinal cords excised.
Every 10th section was stained with the motor neuron marker
rabbit anti-ChAT (since anti-Hb9 was not available) and chicken
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FIGURE 5 | MLR2 is specific for p75NTR and is transported to the
majority of spinal motor neurons after intraperitoneal delivery into
neonatal mice (A–D) Flow cytometry histograms demonstrating
specificity of MLR2-488. Mouse motor neuron-like cells (A), control
ﬁbroblasts (B), human SHSY5Y neuroblastoma cells (C) were incubated with
and without 20 μg of ﬂuorescently labeled anti-p75NTR (MLR2-488) and
ﬂuorescence measured by ﬂow cytometry. X-axis is FITC ﬂuorescence
intensity; Y-axis is number of cells displaying FITC ﬂuorescence. Flow
cytometry histogram from human SHSY5Y (D) incubated with 20 mg
unlabeled MLR2 and then anti-mouse 488 (1/100) is included as control for
MLR2. (E) 488-Fluoresecence observed in lumbar (i), thoracic (iv), and
cervical (vii) regions of spinal cord sections of neonatal C57BL/6J spinal cord
36 h after two intraperitoneal injections of 75 μg of MLR2-488; scale bar:
90 μm. Motor neurons identiﬁed by anti-Hb9 (1/1000; ii,v,viii); also contained
MLR2-488 (iii,vi,xi). (F)The majority of Hb9 labeled motor neurons also
contained MLR2-488. The % of motor neurons containing MLR2-488 was
calculated by counting neurons with Hb9 staining and neurons with
MLR2-488 for 30 μm sections from the lumbar, thoracic and cervical regions
(n = 3 mice with SEM). Motor neurons with MLR2-488-Fluoresecence also
contained p75NTR (G i,ii,iii; scale bar 50 μm). MLR2-488 was also found in
Dorsal root ganglion (from L2-L4; scale bar 80 μm) after intraperitoneal
injections of MLR2-488.
anti-GFP. Representative micrographs show GFP expression in
lumbar, thoracic and cervical spinal cord (Figure 6A i,iv,vii) and
motor neurons identiﬁed by ChAT (Figure 6A ii,v,viii). Merged
images (Figure 6A iii,vi,ix) show that motor neurons identiﬁed by
ChAT also express GFP. Sections taken from control non-injected
animals had no motor neuron staining after being subject to anti-
GFP (Figure 6A x,xi,xii), demonstrating the speciﬁcity of the
anti-GFP. In addition, lumbar sections from mice injected with
PEI-PEG12-pVIVO2 did not have any GFP staining (Figure 6B
i,ii,iii). The GFP expressing neurons from mice injected with
MLR2 PEI-PEG12-pVIVO2 also contained p75NTR (Figure 6C
i,ii,iii). DRGs were also transfected with GFP (Figure 7A). Cells
expressing GFP contained p75NTR (Figures 7B,C). DRGs from
PEI injected animals did not contain GFP (Figures 7D,F) even
though they expressed p75NTR (Figure 7E). As shown in con-
trol sections p75NTR is expressed in a high number of large
diameter cells (Figure 7H) and as expected there was no GFP
staining (Figure 7G). The extent of retrograde transport and gene
expression was assessed for lumbar, thoracic and cervical spinal
cord regions of mice injected with MLR2-PEI-PEG12-pVIVO2 by
counting the number of motor neurons labeled with ChAT and
GFP and with both labels. Figure 6D shows pooled results from
six mice; 25.4 ± 2% lumbar, 18.3 ± 3.4% thoracic and 17 ± 1.7%
of cervical motor neurons from the spinal cord identiﬁed by ChAT
label contained GFP.
DISCUSSION
Despite the fact that a wide range of non-viral gene delivery agents
have been proposed, none have been developed that target motor
neurons from the periphery. Here, we described nanoparticles
that can deliver genes to motor neurons in vivo by an intraperi-
toneal route. We were able to speciﬁcally target motor neurons
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FIGURE 6 | MLR2-PEI-PEG12-pVIVO2 but not PEI-PEG12-pVIVO2 is
retrogradely transported to motor neurons in neonatal mice and GFP
expressed. (A)Two doses of 75 μg of MLR2-PEI-PEG12-pVIVO2 carrying
58 μg pVIVO2 (N/P 12) was injected into neonatal mice and 72 h later spinal
cords excised and examined for GFP expression (n = 5). Motor neurons in
the lumbar (ii), thoracic (iv), and cervical (vii) regions were identiﬁed by
staining with ChAT (1/5000) and GFP expression identiﬁed with chicken
anti-GFP (1/500). Motor neurons that expressed GFP (i,iv,vii) always
contained ChAT (iii scale bar: 100 μm; vi scale bar: 100 μm; ix scale bar:
50 μm). Motor neurons from control sections of untreated mice identiﬁed by
ChAT (xi), did not contain GFP ﬂuorescence (x) after treatment with chicken
anti-GFP (1/500) scale bar: 50 μm. (B)Two doses of 75 μg of
PEI-PEG12-pVIVO2 carrying 77.3 μg pVIVO2 (N/P 5) was injected into
neonatal mice and 72 h later spinal cords excised and examined for GFP
expression (n = 3). Lumbar sections did not contain GFP ﬂuorescence (i)
after treatment with chicken anti-GFP (1/500) and motor neurons were
identiﬁed by ChAT (ii), scale bar: 50 μm. (C) Motor neurons expressing GFP
observed in mice injected with MLR2-PEI-PEG12-pVIVO2 (i) also expressed
p75NTR (1 μg/ml goat anti-p75NTR; ii) scale bar: 50 μmm. (B,C) M.
(D) Percentage of lumbar, thoracic and cervical motor neurons labeled with
GFP and ChAT 48 h after MLR2-PEI-PEG12-pVIVO2 given, i.p. (n = 5 mice
with SEM).
by including in our nanoparticle an antibody to p75NTR (MLR2)
that binds and internalizes into motor neurons (Matusica et al.,
2008).
The ability of p75NTR antibody MLR2 to target our nanopar-
ticles to motor neurons from the periphery was shown by labeled
MLR2 being observed in the majority of spinal motor neurons
following intraperitoneal administration. MLR2 was labeled with
an Atto-488 ﬂuorophore and observed in the majority (near to
90%) of motor neurons identiﬁed by Hb9 staining, which is spe-
ciﬁc to the nucleus of developing spinal motor neurons (Arber
et al., 1999). These observations indicate thatMLR2 is retrogradely
transported to most of the motor neurons after intraperitoneal
delivery. The similar percentage of labeling across the lumbar,
thoracic and cervical regions is not surprising, since motor neu-
rons in all segments of the rodent neonatal spinal cord are known
to express p75NTR (Yan and Johnson, 1988). We also observed
labeled antibody in dorsal root ganglia (DRG). Previous work
has shown the majority of motor neurons and sensory ﬁbers in
the spinal tract can be accessed in an identical manner by intra-
venous or intraperitonealy delivered agents that travel retrogradely
inmotor neurons and sensory ﬁbers. Hence, intraperitoneal routes
to motor neurons and dorsal root ganglia (DRG) that contain cell
bodies of sensory ﬁbers are from the circulation to terminals in
the periphery. This was clearly shown by Alisky et al. (2002) where
both intraperitoneal and intravenous injections of retrograde trac-
ing agent cholera toxin subunit B (CTB) accessed all spinal motor
neurons and produced identical staining. Hence, labeled MLR2
probably travels to the neuromuscular junctions via the circulation
after intraperitoneal injections.
The nanoparticle comprising MLR2 conjugated to PEGylated
PEI, and the GFP expressing plasmid pVIVO2 transfected motor
neurons 72 h post intraperitoneal injections into 5 neonatal mice.
25.4% of lumbar, 18.3% of thoracic, and 17.0% of spinal motor
neurons were transfected with pVIVO2 identiﬁed by GFP expres-
sion. When we injected PEGylated PEI carrying pVIVO2, there
were no motor neurons transfected, demonstrating again that
MLR2 antibody is an important component for retrograde trans-
port tomotor neurons in the spinal cord. This is also demonstrated
by the fact there was no transfection in any other type of spinal
cord cells when PEGylated PEI carrying pVIVO2 was injected
into neonatal mice. Speciﬁcity and retrograde transport of the
immunogene to motor neurons is by MLR2. Motor neurons were
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FIGURE 7 | MLR2-PEI-PEG12-pVIVO2 is retrogradely transported to
dorsal root ganglia (DRG)s in neonatal mice and GFP expressed.Two
doses of 75 μg of MLR2-PEI-PEG12-pVIVO2 carrying 58 μg pVIVO2 (N/P
12) was injected into neonatal mice and 72 h L2-L4 DRGs excised and
examined for GFP expression (n = 5). GFP expression was identiﬁed with
chicken anti-GFP (1/500) and p75NTR with goat anti-p75NTR (1 μg/ml). GFP
ﬂuorescence in DRG sections was detected after treatment with chicken
anti-GFP (1/500;A) that also contained p75NTR (B,C scale bar: 50 μm). Two
doses of 75 μg of PEI-PEG12-pVIVO2 carrying 77.3 μg pVIVO2 (N/P 5) was
also injected into neonatal mice and 72 h later spinal cords excised and
examined for GFP expression (n = 3). DRG sections did not contain GFP
ﬂuorescence (D) in neurons that also contained p75NTR (E,F; scale bar:
50 μm E,F). Control mice non-injected DRG sections did not contain GFP
(G) but did contain p75NTR (H,I; scale bar: 50 μm).
identiﬁed by ChAT. Since motor neurons identiﬁed by ChAT over-
lap with Hb9 staining in neonatal mice, this was a valid analysis
(Shneider et al., 2009). The low level of transfection observed in
motor neurons in vivo may be explained by the reported inef-
ﬁciency of non-viral gene delivery (Mintzer and Simanek, 2009;
Rogers and Rush, 2012). In regards to dosage, we used the same
dosage of nanoparticle as we did labeled antibody (75 μg/g body
weight). Hence since the same amount of antibody (when labeled)
can access all the motor neurons, other areas of the nanoparticle
delivery may not be optimal. Further improvements to transfec-
tion efﬁciency in vivo can be made. We already have a large payload
for our nanoparticle, and although PEI is PEGylated, the whole
IgG (MLR2) was not. A way to reduce interactions of the IgG
with the immune system is to use the antibody binding fragments.
For example, antibody fragments that lack Fc domains (FAb, Fv,
scFv), have reduced interactionswith the immune systemandnon-
targeted cells through Fc receptors (Peer and Lieberman, 2011).
Indeed, previous work with antibody fragments for tumor target-
ing using immunoliposomes carrying plasmid DNA has produced
less immune reaction than whole antibodies and more sustained
expression in vivo (Zhou et al., 2011). Hence, further improve-
ments to transfection efﬁciency may be made by using FAb or
scFV of MLR2 instead of the whole IgG.
This is the ﬁrst report of speciﬁc gene delivery to motor neu-
rons via the circulation. Previous viral gene delivery attempts
to transfect neonatal mouse motor neurons did not have the
speciﬁcity to transfect mouse motor neurons via the circulation
(Towne et al., 2008). Towne et al. (2008) tested intravenous deliv-
ery of recombinant adeno-associated virus (rAAVs) expressing
small hairpin RNAs targeting mutant SOD1 in the ALS mouse
model. Although theAAV virus could transfect mouse motor neu-
rons from the circulation it was not speciﬁc, it also transfected
most other cell types. Towne et al. (2011) then went on to serotype
their AAV viral delivery for retrograde transport and gave multi-
ple injections to muscle groups innervated by motor neurons in
neonatal SOD1 mice. Unfortunately, they could not down regu-
late mutant SOD1 enough to improve outcomes in ALS mice. This
was suggested to be because not all motor neurons were accessed
by intramuscular injections resulting in inconsistent of levels of
transfection across the spinal cord. Notably, approximately 28%
of lumbar, 12% of thoracic, and 18% of cervical motor neurons
were transfected in neonatal mice (Towne et al., 2011). It was con-
cluded that the lack of improvement after their viral gene therapy
might be because it is difﬁcult to access all motor neurons by intra-
muscular injections. In contrast, we were able to achieve motor
neuron transfection after intraperitoneal injections of immuno-
gene. We did not need to inject every muscle group to get speciﬁc
transfection of motor neurons. To our knowledge we are the ﬁrst
group to do so. We have shown that you can transfect 25.4% of
lumbar, 18.3% of thoracic, and 17.0% of spinal motor neurons
after delivery of our immunogene Considering our nanoconstruct
may not still be optimal, our results are hopeful for developing
targeted therapy.
PEI was used to condense plasmid DNA for gene delivery
in vitro and in vivo. However, PEI was modiﬁed by PEGylation
to make it “stealth-like” in the circulation. Our data indicates
that PEGylation reduces the toxicity branched PEI has to pure
motor neurons. The viability of motor neurons in vitro subject
to PEI conjugated to p75NTR targeting antibody MLR2 was sig-
niﬁcantly poorer than PEGylated PEI conjugated to MLR2. This
result was not surprising since previous work has shown PEI with-
out modiﬁcation is toxic (Moghimi et al., 2005) causing cell stress
and apoptosis (Godbey et al., 1999; Moghimi et al., 2005). Other
work has shown modifying PEI by PEGylation reduces cellular
toxicity (Ogris et al., 1999; Malek et al., 2009), presumably by
reduction in positive charge (Merdan et al., 2003; Hoskins et al.,
2012) and the formation of a hydrophilic corona around the
PEI/DNA core (Merdan et al., 2005). Grafting of PEI with PEG
chains thus reduces the zeta potential of PEI-based polyplexes
even at high N/P ratio (Merdan et al., 2005). The zeta potential of
our immunogene were negative at the N/P ratio of 12 used in vitro
and in vivo (Hoskins et al., 2012). Therefore, our results showing
that PEGylated PEI reduces the zeta potential and toxicity of our
immunogene in vitro are consistent with the literature.
Although we were able to transfect motor neurons in vivo, our
immunogene produced a low percentage (∼8%) of transfection
in vitro. This was signiﬁcantly lower than the 17–25% of motor
neurons transfected throughout the spinal cord in vivo. This dis-
parity between in vitro and in vivo transfection is not unusual
for stable cationic constructs containing grafted stealth agents and
targeting agents. For example, Höbel et al. (2011) showed that
despite their relatively low in vitro efﬁcacy, PEI grafted with sugars
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showed better in vivo than in vitro proﬁles and reduced toxicity.
Most testing of non-viral gene delivery agents in vitro employs
cell lines cell that rapidly divide with cell culture reagents that do
not accurately mimic the in vivo situation (van Gaal et al., 2011).
Furthermore, transfection is often undertaken without serum in
the media, which does not mimic the high perecentage of serum
in the circulation. Cationic polyplexes can interact with nega-
tively charged blood components (e.g., proteins, erythrocytes),
followed by the formation of aggregates. Under these conditions,
precipitation can enhance the association of the delivery system
with the cell surface, which can artiﬁcially elevate transfection
rates with agents that are not stable in physiological media. Con-
versely, non-viral agents that are stable in physiological media
often do not transfect efﬁciently in cell culture, leading to the con-
clusion that such systems are not worthy of further consideration.
Another confounding factor with cell culture experiments is that
the nuclear membrane breaks down during cell division, allowing
efﬁcient translocation of DNA into the nucleus of rapidly divid-
ing cells that greatly facilitates transfection (Pérez-Martínez et al.,
2011). We chose to test our nanoconstructs on PMN which do
not divide. Our stable nanoparticle was not only PEGylated but
also cross-linked to an antibody to p75NTR. Previous research
has found that cross-linking amines in PEI increased the stabil-
ity of PEGylated PEI and improved in vivo stability (Neu et al.,
2007; Höbel et al., 2011). Therefore, our results producing sig-
niﬁcant in vivo transfection is probably reﬂective of the difﬁculty
simulating in vivo environments in vitro.
PEGylation of PEI decreases the number of amines available for
condensing plasmid DNA. The size of our immunogene complex
at neutral charge was small (near 100 nm). This is in contrast to
previous reports where branched PEI nanoconstructs complexed
with DNA can be above 300 nm (Ewe et al., 2014). Conjugation to
antibody MLR2 via a disulﬁde bridge, where amines were further
reduced in the PEGylated PEI did not signiﬁcantly increase the size
of the complex. Previous work has shown that positively charged
particles with sizes above 200 nm may be recognized and removed
by the reticuloendothelial system (RES; Dash et al., 1999; Malek
et al., 2009). PEGylation reduces this interaction (Ogris et al., 1999;
Merdan et al., 2005; Malek et al., 2009) and also the size of the
complex.
We observed no obvious off-target effects in the spinal cord
and transfection of cells other than motor neurons in the spinal
cord with our immunogene. Indeed, we did not observe transfec-
tion in any other cell types except for motor neurons. However,
some of the p75NTR expressing cells were transfected the DRGs.
p75NTR is known to be expressed in DRG cells (Yan and Johnson,
1988) and transfection of some of these cells by our immunogene
again highlights the immunogene travels by receptor mediated
retrograde transport to p75NTR expressing cells. The bicistronic
pVIVO2 plasmid we used is speciﬁcally designed for in vivo trans-
fection. The GFP reporter plasmid (pgWiZ) we used for in vitro
transfections contains CpGs in its backbone that are known to
induce immune response in vivo (Davies et al., 2012). pgWiZ is
often used to improve humoral immune response to plasmid vac-
cination in vivo (Chamarthy et al., 2003; Grønevik et al., 2005; Rose
et al., 2014). In contrast, pVIVO2 has minimal CpGs in its plasmid
backbone and high levels of constitutive transgene expression has
been reported for this plasmid in vivo (Mandke and Singh, 2012).
In addition, pVIVO2 has DTS to improve nuclear entry into post
mitotic cells such as motor neurons. We tried delivering pgWiZ to
motor neurons by intraperitoneal injections with our immuno-
porter MLR2-PEI-PEG12, but found no signiﬁcant expression
in vivo. This has led us to us to conclude that plasmid design
is an important component of effective non-viral gene delivery
agents.
Speciﬁc delivery of genes to motor neurons is highly relevant
to therapy of ALS and spinal muscular atrophy (SMA), where cur-
rently no effective therapy exists (Sreedharan and Brown, 2013).
Our results show thatmotorneurons canbe speciﬁcally transfected
with peripherally administered immunogenes. Targeting motor
neurons by use of the p75NTR is not surprising as this receptor
is highly expressed in the embryonic period and early neonatal
life (Yan and Johnson, 1988). Lentivirus that expressed heavy and
light chains of rat p75NTRantibody (MC192)were recently shown
transported retrogradely from the axonal tip to the cell body in an
in vitro microﬂuidic culture model (Eleftheriadou et al., 2014).
This is in agreement with our in vivo data where p75NTR anti-
body was found throughout the spinal cord after intraperitoneal
delivery, indicating retrograde transport from terminals to ven-
tral motor neurons throughout the spinal cord. Caution has to be
takenwith immunogenes use inALS. p75NTR is down regulated in
adulthood and re-expressed in injury, including ALS (Lowry et al.,
2001). However, the level of p75NTR re-expression and health
of the motor neurons must be sufﬁcient for retrograde trans-
port in the majority of motor neurons. A previous study (Copray
et al., 2003) indicated 5% of L4 Lumbar motor neurons re-express
p75NTR in adult ALS mice at symptomatic age. Further work is
needed todetermine if sufﬁcient therapeutic genes canbedelivered
in adult ALS animal models via p75NTR targeting immunogenes.
Since SMA is a disease often occuring in childhood (Arnold and
Burghes, 2013), p75NTR targeting immunogenes could be trialed
in SMA mice.
CONCLUSION
Our current research demonstrates the suitability of p75NTR
targeting immunogenes to transfect motor neurons from the
periphery in neonatal mice, but further work is required for use in
adult animals.
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